Related Experiment Videos
Vigabatrin in the treatment of epilepsy in children
J H Livingston1, D Beaumont, A Arzimanoglou
1Hopital Necker - Enfants Malades, Paris, France.
Insights
Vigabatrin shows promise as an add-on therapy for refractory childhood epilepsy, with 25% of patients achieving significant seizure reduction. This preliminary study suggests vigabatrin is a safe and potentially effective treatment option for severe pediatric epilepsy.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
- Epileptology
Background:
- Refractory epilepsy in children poses significant treatment challenges.
- Exploring novel therapeutic options is crucial for improving seizure control and quality of life.
Purpose of the Study:
- To evaluate the preliminary efficacy and safety of vigabatrin as an add-on therapy in children with refractory epilepsy.
- To determine optimal dosing strategies and identify potential adverse events.
Main Methods:
- An open-label, non-controlled, multicentre study involving 135 children (2 months-12 years) with various seizure types.
- Vigabatrin was administered as an add-on to existing antiepileptic drugs, with flexible dosing adjustments.
- Seizure frequency, efficacy, and adverse events were monitored.
Main Results:
- A 75-100% seizure reduction was observed in 25% of patients, with 11 becoming seizure-free.
- Efficacy was notably higher in partial seizures (49% good to excellent results).
- Vigabatrin was generally well-tolerated, with most patients reporting no side effects; common adverse events included agitation and somnolence.
Conclusions:
- Vigabatrin demonstrates potential as a safe and effective add-on treatment for severe refractory epilepsy in children.
- Further controlled studies are warranted to confirm these preliminary findings and establish definitive treatment guidelines.
Abstract:
1. This study presents the results of the preliminary screening of vigabatrin as add-on therapy in an open, non-controlled multicentre study in children with refractory epilepsy. 2. There were 135 children, with an age range of 2 months-12 years. Main seizure type was partial in 42%, generalized in 29%, Lennox-Gastaut syndrome in 19% and West syndrome in 10%. 3. Vigabatrin was added onto current antiepileptic treatment in an initially recommended dose of 40-80 mg kg-1 day-1. However, the doses were frequently increased when tolerance allowed it, and the final mean dose used was 87 mg kg-1 day-1 (27-600). 4. A 75% to 100% reduction in seizure frequency was observed in 25% of patients (11 patients became seizure free) and 50 to 75% decrease in a further 13%. Efficacy was better in partial seizures, with good to excellent results in 49% of patients. The use of high doses, above 100 mg kg-1 day, was not associated with greater efficacy in this preliminary study. 5. No side effects were reported in 79% of patients. Agitation and insomnia were observed in 8.8% and somnolence in 6%. Other adverse events included ataxia (2.2%), nausea (2.2%) and increased appetite (1%). A moderate and transient decrease in haemoglobin was reported in six patients from the same centre; these patients were all receiving very high doses of vigabatrin (250 to 600 mg kg-1 day-1). 6. Vigabatrin thus appears to be a safe antiepileptic drug that may be effective in the treatment of severe epilepsy in children.